Noninferiority  	Noninferiority  	 NNP	B-NP
of  	of  	 IN	I-NP
incobotulinumtoxinA 	incobotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
free  	free  	 JJ	O
from  	from  	 IN	O
complexing  	complexing  	 JJ	B-NP
proteins 	proteins 	 NNS	I-NP
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
another  	another  	 DT	O
botulinum  	botulinum  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
A  	A  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
frown  	frown  	 JJ	I-NP
lines  	lines  	 NNS	I-NP
Use  	Use  	 NN	I-NP
of  	of  	 IN	I-NP
botulinum  	botulinum  	 JJ	I-NP
toxin  	toxin  	 NN	I-NP
for  	for  	 IN	I-NP
esthetic  	esthetic  	 JJ	I-NP
purposes  	purposes  	 NNS	I-NP
has  	has  	 VBZ	O
rapidly  	rapidly  	 RB	O
expanded  	expanded  	 VBN	O
over  	over  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
20  	20  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
IncobotulinumtoxinA 	IncobotulinumtoxinA 	 NNP	B-NP
,  	,  	 ,	O
also  	also  	 RB	O
known  	known  	 VBN	O
as  	as  	 IN	O
NT  	NT  	 NNP	B-NP
201 	201 	 CD	O
,  	,  	 ,	O
is  	is  	 VBZ	O
a  	a  	 DT	O
new  	new  	 JJ	O
botulinum  	botulinum  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
( 	( 	 -LRB-	O
150  	150  	 CD	O
kDa 	kDa 	 NN	B-NP
)  	)  	 -RRB-	O
that  	that  	 WDT	O
is  	is  	 VBZ	O
free  	free  	 JJ	O
from  	from  	 IN	O
complexing  	complexing  	 JJ	B-NP
proteins 	proteins 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
prospective 	prospective 	 JJ	O
,  	,  	 ,	O
multicenter 	multicenter 	 NN	B-NP
,  	,  	 ,	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
rater-  	rater-  	 JJ	B-NP
and  	and  	 CC	O
patient-blind 	patient-blind 	 JJ	B-NP
,  	,  	 ,	O
international  	international  	 JJ	O
Phase  	Phase  	 NNP	O
III  	III  	 NNP	O
trial  	trial  	 NN	O
to  	to  	 TO	O
investigate  	investigate  	 VB	O
the  	the  	 DT	O
noninferiority  	noninferiority  	 NN	B-NP
of  	of  	 IN	O
incobotulinumtoxinA  	incobotulinumtoxinA  	 JJ	O
to  	to  	 TO	O
another  	another  	 DT	O
botulinum  	botulinum  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
A 	A 	 NN	O
,  	,  	 ,	O
onabotulinumtoxinA 	onabotulinumtoxinA 	 NNP	B-NP
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
frown  	frown  	 JJ	I-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
381  	381  	 CD	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
randomized  	randomized  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
3 	3 	 CD	O
: 	: 	 :	O
1  	1  	 CD	O
( 	( 	 -LRB-	O
incobotulinumtoxinA 	incobotulinumtoxinA 	 NNP	B-NP
: 	: 	 :	O
onabotulinumtoxinA 	onabotulinumtoxinA 	 NNP	B-NP
)  	)  	 -RRB-	O
ratio  	ratio  	 NN	O
to  	to  	 TO	O
receive  	receive  	 VB	O
24  	24  	 CD	O
U  	U  	 NNP	B-NP
incobotulinumtoxinA  	incobotulinumtoxinA  	 NNP	I-NP
of  	of  	 IN	O
or  	or  	 CC	O
onabotulinumtoxinA 	onabotulinumtoxinA 	 JJ	O
.  	.  	 .	O
Efficacy  	Efficacy  	 JJ	B-NP
end  	end  	 NN	I-NP
points  	points  	 NNS	I-NP
included  	included  	 VBD	O
the  	the  	 DT	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
responders  	responders  	 NNS	B-NP
( 	( 	 -LRB-	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
an  	an  	 DT	O
improvement  	improvement  	 NN	O
of  	of  	 IN	O
≥1  	≥1  	 CD	O
point  	point  	 NN	O
on  	on  	 IN	O
a  	a  	 DT	O
4-point  	4-point  	 JJ	O
facial  	facial  	 JJ	B-NP
wrinkle  	wrinkle  	 NN	I-NP
scale 	scale 	 NN	I-NP
)  	)  	 -RRB-	O
at  	at  	 IN	O
maximum  	maximum  	 JJ	O
frown  	frown  	 NN	O
at  	at  	 IN	O
weeks  	weeks  	 NNS	O
4  	4  	 CD	O
and  	and  	 CC	O
12  	12  	 CD	O
as  	as  	 IN	O
assessed  	assessed  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
investigators 	investigators 	 NNS	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
a  	a  	 DT	O
panel  	panel  	 NN	O
of  	of  	 IN	O
independent  	independent  	 JJ	O
raters  	raters  	 NNS	B-NP
based  	based  	 VBN	O
on  	on  	 IN	O
standardized  	standardized  	 JJ	O
digital  	digital  	 JJ	B-NP
photographs 	photographs 	 NNS	I-NP
.  	.  	 .	O
Four  	Four  	 CD	O
weeks  	weeks  	 NNS	O
after  	after  	 IN	O
injection 	injection 	 NN	B-NP
,  	,  	 ,	O
response  	response  	 NN	B-NP
rates  	rates  	 NNS	I-NP
at  	at  	 IN	O
maximum  	maximum  	 JJ	O
frown  	frown  	 NN	O
were  	were  	 VBD	O
96.4 	96.4 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
incobotulinumtoxinA  	incobotulinumtoxinA  	 JJ	B-NP
group  	group  	 NN	I-NP
and  	and  	 CC	O
95.7 	95.7 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
onabotulinumtoxinA  	onabotulinumtoxinA  	 JJ	B-NP
group  	group  	 NN	I-NP
as  	as  	 IN	O
assessed  	assessed  	 VBN	O
by  	by  	 IN	O
independent  	independent  	 JJ	O
raters 	raters 	 NN	B-NP
.  	.  	 .	O
Analysis  	Analysis  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
data  	data  	 NNS	O
confirmed  	confirmed  	 VBD	O
the  	the  	 DT	O
noninferiority  	noninferiority  	 NN	B-NP
of  	of  	 IN	O
incobotulinumtoxinA 	incobotulinumtoxinA 	 JJ	O
.  	.  	 .	O
Response  	Response  	 NN	B-NP
rates  	rates  	 NNS	I-NP
at  	at  	 IN	O
rest  	rest  	 NN	O
were  	were  	 VBD	O
lower  	lower  	 JJR	O
for  	for  	 IN	O
both  	both  	 DT	O
products 	products 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
rate  	rate  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
was  	was  	 VBD	O
low 	low 	 JJ	O
.  	.  	 .	O
IncobotulinumtoxinA  	IncobotulinumtoxinA  	 NNP	B-NP
is  	is  	 VBZ	O
equally  	equally  	 RB	O
as  	as  	 IN	O
effective  	effective  	 JJ	O
as  	as  	 IN	O
onabotulinumtoxinA  	onabotulinumtoxinA  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
frown  	frown  	 JJ	I-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
Both  	Both  	 DT	O
preparations  	preparations  	 NN	B-NP
were  	were  	 VBD	O
well  	well  	 RB	O
tolerated 	tolerated 	 VBN	O
.  	.  	 .	O
